Cantor Fitzgerald Estimates Legend Biotech FY2025 Earnings

Legend Biotech Co. (NASDAQ:LEGN) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Legend Biotech in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst R. Bienkowski forecasts that the company will post earnings of ($0.72) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $83.00 target price on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.24) per share.

Legend Biotech (NASDAQ:LEGN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.22. The company had revenue of $160.20 million for the quarter, compared to analyst estimates of $143.91 million. Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.69%. The business’s revenue for the quarter was up 66.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.17) earnings per share.

Several other analysts have also recently weighed in on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $78.00 target price on shares of Legend Biotech in a report on Monday, December 30th. Royal Bank of Canada reiterated an “outperform” rating and set a $86.00 target price on shares of Legend Biotech in a research note on Monday, December 9th. Redburn Atlantic initiated coverage on Legend Biotech in a research note on Tuesday, October 8th. They issued a “buy” rating and a $86.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $73.00 price objective on shares of Legend Biotech in a research report on Tuesday. Thirteen analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $80.62.

Legend Biotech Price Performance

LEGN opened at $34.67 on Wednesday. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.98 and a quick ratio of 4.90. The business has a fifty day moving average price of $36.59 and a 200 day moving average price of $45.91. Legend Biotech has a 12 month low of $30.17 and a 12 month high of $70.13.

Hedge Funds Weigh In On Legend Biotech

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quantbot Technologies LP acquired a new stake in Legend Biotech during the 3rd quarter worth approximately $148,000. SG Americas Securities LLC acquired a new position in Legend Biotech in the 3rd quarter valued at $212,000. Public Employees Retirement System of Ohio purchased a new position in Legend Biotech during the 3rd quarter worth $229,000. Vanguard Personalized Indexing Management LLC lifted its stake in shares of Legend Biotech by 31.6% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 6,540 shares of the company’s stock worth $290,000 after acquiring an additional 1,571 shares during the period. Finally, Aigen Investment Management LP purchased a new stake in shares of Legend Biotech in the third quarter valued at about $300,000. Hedge funds and other institutional investors own 70.89% of the company’s stock.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).